Natalia Kubanek

Natalia Kubanek

Auto-generated profile, based on publicly available information

Natalia Kubanek

Department of Internal Medicine II, Division of Hepatology, Gastroenterology and Liver Transplantation, Slovak Medical University, F.D. Roosevelt University Hospital, Banska Bystrica, Slovak Republic

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2024 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
CRCarolina Ramirez‐Cadiz
Carolina Ramirez‐Cadiz
HBHanna Blaney
Hanna Blaney
NKNatalia Kubanek
Natalia Kubanek
LDLuis Antonio Díaz
Luis Antonio Díaz
RLRohit Loomba
Rohit Loomba
JAJuan Pablo Arab
Juan Pablo Arab
Summary: Background: Alcohol‐associated hepatitis (AH) is a severe inflammatory form of alcohol‐associated liver disease (ALD) that carries a high mortality rate. Early liver transplantation for severe AH is increasingly available. However, specific criteria for referral and selection remain a subject of debate.Aims: To provide a narrative review of the natural history, diagnostic criteria and indications for referral for early liver transplantation for severe AH.Methods: We searched PubMed for articles published through August 2023. Key search terms were ‘alcoholic hepatitis,’ ‘alcohol‐associated hepatitis,’ ‘abstinence,’ ‘alcohol relapse,’ and ‘liver transplantation.’Results: Previously, a six‐month period of alcohol abstinence was required before patients with ALD were considered for liver transplantation. However, studies in recent years have demonstrated that, among carefully selected patients, patients who received early transplants have much higher survival rates than patients with similarly severe disease who did not undergo transplants (77% vs. 23%). Despite these successes, early liver transplantation remains controversial, as these patients have typically not undergone treatment for alcohol use disorder, with the ensuing risk of returning to alcohol use.Conclusions: While early liver transplantation for AH has survival benefits, many patients would not have received treatment for alcohol use disorder. An integrated approach to evaluating candidacy for early liver transplantation is needed.

31 October 2024 in EPMA Journal
Verified
Journal Article
Open access
PDF file
LSLubomir Skladany
Lubomir Skladany
NKNatalia Kubanek
Natalia Kubanek
SASvetlana Adamcova-Selcanova
Svetlana Adamcova-Selcanova
DŽDaniela Žilinčanová
Daniela Žilinčanová
DHDaniel Havaj
Daniel Havaj
JAJuan Pablo Arab
Juan Pablo Arab
Rationale: Severe alcohol-associated hepatitis (SAH) is the most critical, acute, inflammatory phenotype within the alcohol-associated liver disease (ALD) spectrum, characterized by high 30- and 90-day mortality. Since several decades, corticosteroids (CS) are the only approved pharmacotherapy offering highly limited survival benefits. Contextually, there is an evident demand for 3PM innovation in the area meeting patients’ needs and improving individual outcomes. Fecal microbiota transplantation (FMT) has emerged as one of the new potential therapeutic options. In this study, we aimed to address the crucial 3PM domains in order to assess (i) the impact of FMT on mortality in SAH patients beyond CS, (ii) to identify factors associated with the outcome to be improved (iii) the prediction of futility, (iv) prevention of suboptimal individual outcomes linked to increased mortality, and (v) personalized allocation of therapy. Methods: We conducted a prospective study (NCT04758806) in adult patients with SAH who were non-responders (NR) to or non-eligible (NE) for CS between January 2018 and August 2022. The intervention consisted of five 100 ml of FMT, prepared from 30 g stool from an unrelated healthy donor and frozen at − 80 °C, administered daily to the upper gastrointestinal (GI) tract. We evaluated the impact of FMT on 30- and 90-day mortality which we compared to the control group selected by the propensity score matching and treated by the standard of care; the control group was derived from the RH7 registry of patients hospitalized at the liver unit (NCT04767945). We have also scrutinized the FMT outcome against established and potential prognostic factors for SAH — such as the model for end-stage liver disease (MELD), Maddrey Discriminant Function (MDF), acute-on-chronic liver failure (ACLF), Liver Frailty Index (LFI), hepatic venous-portal pressure gradient (HVPG) and Alcoholic Hepatitis Histologic Score (AHHS) — to see if the 3PM method assigns them a new dimension in predicting response to therapy, prevention of suboptimal individual outcomes, and personalized patient management. Results: We enrolled 44 patients with SAH (NR or NE) on an intention-to-treat basis; we analyzed 33 patients per protocol for associated factors (after an additional 11 being excluded for receiving less than 5 doses of FMT), and 31 patients by propensity score matching for corresponding individual outcomes, respectively. The mean age was 49.6 years, 11 patients (33.3%) were females. The median MELD score was 29, and ACLF of any degree had 27 patients (81.8%). FMT improved 30-day mortality (p = 0.0204) and non-significantly improved 90-day mortality (p = 0.4386). Univariate analysis identified MELD ≥ 30, MDF ≥ 90, and ACLF grade > 1 as significant predictors of 30-day mortality, (p = 0.031; p = 0.014; p = 0.034). Survival was not associated with baseline LFI, HVPG, or AHHS. Conclusions and recommendations in the framework of 3PM: In the most difficult-to-treat sub-cohort of patients with SAH (i.e., NR/NE), FMT improved 30-day mortality. Factors associated with benefit included MELD ≤ 30, MDF ≤ 90, and ACLF < 2. These results support the potential of gut microbiome as a therapeutic target in the context of 3PM research and vice versa — to use 3PM methodology as the expedient unifying template for microbiome research. The results allow for immediate impact on the innovative concepts of (i) personalized phenotyping and stratification of the disease for the clinical research and practice, (ii) multilevel predictive diagnosis related to personalized/precise treatment allocation including evidence-based (ii) prevention of futile and sub-optimally effective therapy, as well as (iii) targeted prevention of poor individual outcomes in patients with SAH. Moreover, our results add to the existing evidence with the potential to generate new research along the SAH’s pathogenetic pathways such as diverse individual susceptibility to alcohol toxicity, host-specific mitochondrial function and systemic inflammation, and the role of gut dysbiosis thereof.

24 October 2024 in Hepatology Communications
Verified
Journal Article
Open access
AIAlvi Husni Islam
Alvi Husni Islam
LDLuis Antonio Díaz
Luis Antonio Díaz
FIFrancisco Idalsoaga
Francisco Idalsoaga
LGLeonardo Guizzetti
Leonardo Guizzetti
RMRokhsana Mortuza
Rokhsana Mortuza
JAJuan Pablo Arab
Juan Pablo Arab
Export

19 July 2024 in United European Gastroenterology Journal
Verified
Journal Article
Open access
TKTomas Koller
Tomas Koller
PVPetra Vrbova
Petra Vrbova
NKNatalia Kubanek
Natalia Kubanek
DŽDaniela Žilinčanová
Daniela Žilinčanová
SASvetlana Adamcova-Selcanova
Svetlana Adamcova-Selcanova
LSLubomir Skladany
Lubomir Skladany
Background and aims: Intestinal inflammation assessed by fecal calprotectin (F‐CAL) in advanced chronic liver disease (ACLD) may represent an early sign of intestinal barrier dysfunction. We aimed to explore the usefulness of F‐CAL testing in ACLD in the prediction of adverse outcomes (AO, death, or LT) and refinement of prognostic stratification.Patients and methods: We explored the RH7 cirrhosis registry comprising consecutive hospitalized patients and a control group with data on disease phenotype, demographics, anthropometrics, prognostic indices, and medication. The F‐CAL was evaluated on admission and reported in multiples of the upper limit of normal or terciles. Predictive power was tested in the Cox model for AO over 180 days. Additional risk refinement by F‐CAL was tested for both groups.Results: We enrolled 263 cases in the study group with a median age of 57.2 years, M/F ratio 167/96, with alcohol, metabolic dysfunction‐associated steatotic liver disease, MetALD, and viral etiologies in 72.2%, 9.1, 8.0, 3.4%. The median F‐CAL was 3.92 × ULN. The control group comprised 108 cases. The adjusted Cox model confirmed F‐CAL (hazard ratio [HR] = 1.05, p < 0.001) and F‐CAL terciles (HR = 1.413, p = 0.009) as independent predictors of AO. F‐CAL terciles had higher predictive accuracy in CLIF‐C‐AD11 × ULN) could identify patients having 2–3 times higher risk of AO. This approach has been validated in the control group.Conclusion: Among hospitalized patients with ACLD, F‐CAL values were independently proportional to the risk of AO, particularly in early disease stages when high F‐CAL values could refine prognostic stratification.

19 January 2025 in Alcohol and Alcoholism
Verified
Journal Article
Open access
LSLubomir Skladany
Lubomir Skladany
DŽDaniela Žilinčanová
Daniela Žilinčanová
NKNatália Kubánek
Natália Kubánek
SASvetlana Adamcova-Selcanova
Svetlana Adamcova-Selcanova
DHDaniel Havaj
Daniel Havaj
TKTomas Koller
Tomas Koller
Background and aims: Alcohol-associated hepatitis (AH) frequently triggers acute decompensation (AD) in cirrhosis, with severe AH linked to high short-term mortality, especially in acute-on-chronic liver failure. Current corticosteroid treatments have limited efficacy, highlighting the need for new therapies. We hypothesized that severe AH outcomes are influenced by early specialized care; thus, we examined the impact of time-to-tertiary care (TTTc). Methods: Adults with cirrhosis or advanced chronic liver disease were enrolled (RH7, NCT04767945). AH was diagnosed using National Institute on Alcohol Abuse and Alcoholism criteria. Primary admission site, TTTc, and adverse outcomes (death or liver transplantation) were analyzed. Patients admitted directly to tertiary care were assigned a TTTc of zero. Results: Of 221 AD-AH patients, 107 were transferred from secondary care to tertiary care (TTTc >0) and 114 were admitted directly (TTTc = 0). TTTc >0 patients were younger (48.3 vs. 52 years, P = .008) and had more severe disease, as shown by model for end-stage liver disease scores (25.5 vs. 20.8, P < .001) and Maddrey’s discriminant function (59.3 vs. 40.6, P < .001). Propensity-score matching yielded 49 case pairs. The Cox model showed that transfer from secondary care was not associated with increased risk, but delayed transfer (days, hazard ratio = 1.03, 95% confidence interval 1.01–1.05) independently predicted adverse outcomes. Conclusions: Delayed initiation of specialized care adversely impacts outcomes in AD-AH. If validated, timely care bundles could improve AH survival, similar to sepsis or vascular syndromes. Highlights: AD-AH is a common syndrome associated with high short-term mortality. There is an unmet need for new prognosis-modifying therapies for AH. Currently, in real-life hepatology, refining the existing bundle of care is the only practical option to improve the prognosis of AD-AH. Past experience with acute coronary syndromes, stroke, and sepsis, emphasizing symptoms-to-intervention duration, combined with the recent COVID-19 lockdown finding of increased mortality due to skewed access to specialized liver care indicates that focusing on timely specialized care might be key to improved outcome in certain liver conditions. In this line, we set out to track the number of days elapsing between admission to SC and referral to TC, coining this interval as “time-to-tertiary care” (TTTc). We examined TTTc as a potential compound surrogate that might influence the prognosis in AD-AH. After correcting for important baseline differences, we conclude that the delay of transfer to the tertiary care hospital was independently associated with a worse prognosis with each additional day in TTTc increasing adverse outcomes by nearly 3%.

17 April 2026 in Gastroenterologie a hepatologie
Verified
Journal Article
Open access
PDF file
NKNatália Kubánek
Natália Kubánek
SSSvetlana Adamcová Selčanová
Svetlana Adamcová Selčanová
DŽDaniela Žilinčanová
Daniela Žilinčanová
KŠKarolína Kristína Šulejová
Karolína Kristína Šulejová
DHDaniel Ján Havaj
Daniel Ján Havaj
ĽSĽubomír Skladaný
Ľubomír Skladaný
Invazívne fungálne infekcie patria medzi závažné infekčné komplikácie u pacientov po transplantácii pečene s vysokou morbiditou a mortalitou. Aspergilóza je druhou najčastejšou z invazívnych mykóz a vo väčšine prípadov sa vyskytuje v diseminovanej forme s postihnutím viacerých orgánov. Izolované postihnutie CNS sa považuje za vzácnu komplikáciu. V našej kazuistike prezentujeme prípad pacienta po transplantácii pečene, u ktorého sa vo včasnom posttransplantačnom období rozvinuli bolesti hlavy, ku ktorým sa neskôr pridružili poruchy zraku. Po niekoľkých mesiacoch od začiatku symptómov prinieslo definitívnu ­gnózu až histologické vyšetrenie lézie lokalizovanej na klinovej kosti lebky s potvrdením infekcie vyvolanej Aspergillus spp. U pacienta bola zahájená antimykotická liečba podľa odporúčaní infektológa s následným frekventným monitorovaním hladín imunosupresív v ambulantnom sledovaní.